Key result
CamAPS FX closed-loop system maintains ~88% postpartum time in range during complicated infective endocarditis.
Why the study?
Managing glycemic control in type 1 diabetes during pregnancy remains complex and critical to reduce maternal and fetal risks.
Does the CamAPS FX advanced hybrid closed-loop system maintain optimal glycemic control in a pregnant patient with type 1 diabetes during pregnancy and a complicated postpartum hospitalization?
Case Report (n=1)
Does the CamAPS FX advanced hybrid closed-loop system maintain optimal glycemic control in a pregnant patient with type 1 diabetes during pregnancy and a complicated postpartum hospitalization?
The CamAPS FX advanced hybrid closed-loop system safely and effectively maintained optimal glycemic control in a patient with type 1 diabetes during pregnancy, labor, and a complicated postpartum hospitalization for tricuspid valve infective endocarditis.
Supports feasibility of hybrid closed-loop systems in complicated T1D pregnancies; hypothesis-generating and requires prospective validation.
Managing glycemic control in type 1 diabetes during pregnancy is still very complex and extremely important to reduce maternal and fetal risks. We present the case of a 36-year-old woman with type 1 diabetes mellitus managed throughout her pregnancy with an advanced hybrid closed-loop (AHCL) CamAPS FX. Glycemic control during pregnancy was optimal, with a time in range (64-140 mg/dL) in the second and third trimesters > 75%. No serious episodes of hypoglycemia or ketoacidosis occurred. A vaginal delivery occurred at the 39th week, with a favorable neonatal outcome (birth weight 3,418 g, Apgar score 8/9). The uniqueness of this clinical case is related to the fact that the patient experienced several postpartum complications: hospitalization for tricuspid valve endocarditis, which initially manifested with pulmonary embolism. The postpartum period, characterized by breastfeeding, changes in sleep-wake rhythm, newborn care, infectious disease, antibiotics, and hospitalization, was managed by the algorithm. The insulin pump was never interrupted and continued with the support of the diabetes team, achieving optimal glycemic control throughout the postpartum period until the acute condition resolved with a time in range (70-180 mg/dL) of 88%. The CamAPS system in our case has therefore proven to be effective, safe, and adaptable during pregnancy, the postpartum period, and hospitalization during the acute phase of the disease.
No takes yet. Share an insight, caveat, or question.
Galasso et al. (2025) conducted a case report in Type 1 diabetes mellitus in pregnancy and postpartum (n=1). CamAPS FX Advanced Hybrid Closed-Loop (AHCL) System was evaluated on Glycemic control (Time in Range). The CamAPS FX advanced hybrid closed-loop system maintained optimal glycemic control, with a time in range >75% during pregnancy and 88% during a complicated postpartum hospitalization for infective endocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: